Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventor Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • The PATLIB Knowledge Transfer to Africa initiative (KT2A)
          • KT2A core activities
          • Success story: Malawi University of Science and Technology and PATLIB Birmingham
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Innovation against cancer
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 0236/01 (Domain-modified antibodies/COLUMBIA UNIVERSITY) 15-09-2005
Facebook X Linkedin Email

T 0236/01 (Domain-modified antibodies/COLUMBIA UNIVERSITY) 15-09-2005

European Case Law Identifier
ECLI:EP:BA:2005:T023601.20050915
Date of decision
15 September 2005
Case number
T 0236/01
Petition for review of
-
Application number
89301052.0
IPC class
C12N 15/00
Language of proceedings
EN
Distribution
DISTRIBUTED TO BOARD CHAIRMEN (C)

Download and more information:

Decision in EN 82.56 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Domain-modified constant region antibodies

Applicant name
The Trustees of Columbia University in the City of New York
Opponent name
Celltech Therapeutics Ltd.
Board
3.3.08
Headnote
-
Relevant legal provisions
European Patent Convention Art 54 1973
European Patent Convention Art 113(1) 1973
European Patent Convention Art 123(2) 1973
Keywords

Main request and first auxiliary request - appeal not substantiated

Second and third auxiliary requests - undisclosed disclaimer not allowable - added matter (yes)

Auxiliary requests IV to IX - added matter (yes)

Catchword
-
Cited decisions
G 0001/03
G 0002/03
T 0939/92
T 1050/99
Citing decisions
T 0795/05
T 1107/06

I. The appeal lies against the decision of the opposition division posted 13 December 2000 revoking European patent No. 0 327 378, entitled "Domain-modified constant region antibodies" and granted with 21 claims for all designated Contracting States on the basis of European patent application No. 89 301 052.0.

II. An opposition had been filed on the grounds of Article 100(a) EPC and Article 100(b) EPC, in particular lack of novelty (Article 54 EPC), lack of inventive step (Article 56 EPC) and insufficient disclosure of the claimed subject-matter in the patent as granted. The opposition division found that the main request (claims as granted) did not fulfil the requirements of Article 54 EPC, the subject-matter of claim 1 lacking novelty over documents D6 and D10. Furthermore, the opposition division held that none of the three auxiliary requests on file (first auxiliary request based on an amended claim 1 filed on 30 July 1998, and second and third auxiliary requests as filed on 18 August 2000) was allowable, the negative features introduced into their respective claims 1 being in breach of Article 123(2) EPC. Claim 1 of the first auxiliary request was found also not to fulfil the requirements of Article 84 EPC.

III. Granted claim 1 (main request) read as follows:

"1. An antibody chain having at least one binding site region and a domain-modified constant region, wherein said domain-modified constant region comprises a modification selected from the group consisting of

(1) an insertion of at least eighty percent of the amino acids of at least one of the domains of CL, CH1, hinge, CH2, CH3, and CH4, wherein the rest of the domain-modified constant region has the same amino acid sequence as that of a constant region of a mammalian antibody,

(2) a substitution of at least eighty percent of the amino acids of at least one of the domains of CL, CH1, hinge, CH2, CH3, or CH4 by at least eighty percent of the amino acids of at least one but less than all of said domains from a different mammalian antibody chain, wherein the rest of the domain-modified constant region has at least eighty percent the same amino acid sequence as that of a constant region of a mammalian antibody and

(3) a deletion of at least eighty percent of the amino acids of more than one of the domains CH1, hinge, CH2, CH3, or CH4, wherein the remaining amino acids of the domain-modified constant region have at least eighty percent the same amino acid sequence as that of at least one domain of a constant region of a mammalian antibody."

Claims 2 to 11 as granted were directed to different embodiments of the antibodies of claim 1. Claims 12 to 18 concerned DNA constructs encoding domain-modified antibody chains, and claims 19 and 20 a cell containing the claimed DNA constructs. Finally, claim 21 related to a method for producing a domain-modified constant region antibody.

IV. The first auxiliary request (claims 1 to 21) differed from the main request solely in that its claim 1 included the following provisos:

"...

(a) that the insertion of (1) is not a duplication of a hinge domain;

(b) that the deletion is other than deletion of constant region containing the domains CH2 and CH3; and

(c) that the substitution of (2) is not the substitution of the hinge of IgG1 with the hinge of IgG4."

V. Claim 1 of the second auxiliary request (claims 1 to 7) read:

"1. A secreted monoclonal antibody which comprises two heavy chains and two light chains assembled into a Y-shape configuration wherein:

(a) the antibody has a desired antigen specificity; and

(b) each heavy chain of the antibody comprises at least one binding site region from a mammalian source and a domain-modified human constant region, wherein said domain-modified constant region comprises a modification relative to an unmodified heavy chain of a human antibody from a human source, which modification is selected from the group consisting of:

(1) an insertion of at least 80% of the amino acids of at least one of the domains of CL, CH1, hinge, CH2, CH3, and CH4 from said human antibody or from a different human antibody, wherein the rest of the domain-modified human constant region has the same amino acid sequence as that of a constant region of said unmodified heavy chain of said human antibody,

(2) a substitution of at least 80% of the amino acids of at least one of the domains of CH1, hinge, CH2, and CH3 by at least 80% of the amino acids of at least one but less than all of CL, CH1, hinge, CH2, CH3, and CH4 from a different human antibody, wherein the rest of the domain-modified constant region has at least 80% of the same amino acid sequence as that of a constant region of said unmodified heavy chain of said human antibody, and

(3) a deletion of at least 80% of the amino acids of more than one of the domains CH1, hinge, CH2, and CH3 of said human antibody, wherein the remaining amino acids of the domain-modified constant region have at least 80% the same amino acid sequence as that of at least one domain of a constant region of said unmodified heavy chain of said human antibody;

and wherein said human antibody is an IgG1 through IgG4 subclass antibody with the proviso that said human antibody is not an IgG3 subclass antibody."

Claims 2 to 6 were directed to embodiments of the antibody of claim 1, and claim 7 to a method for producing the claimed antibody.

VI. The third auxiliary request (claims 1 to 7) differed from the previous request in that the additional feature

"(c) the antibody has carbohydrate attached to it"

was inserted at the end of claim 1.

VII. The appellant (proprietor of the patent) filed an appeal against the revocation of the patent and paid the appeal fee. With the statement of grounds of appeal, the appellant filed six new auxiliary requests (auxiliary requests IV to IX), the main request and the auxiliary requests I to III on which the decision of the opposition division was based, being maintained on appeal. As a subsidiary request, oral proceedings pursuant to Article 116 EPC were requested.

VIII. Claim 1 of auxiliary request IV (claims 1 to 9) reads:

"1. An antibody fragment which comprises a half antibody formed from a single light chain and a single heavy chain assembled to produce a specific binding site,

which heavy chain has at least one binding site region from a mammalian source and a domain-modified human constant region,

which domain-modified human constant region comprises a deletion of at least 80% of the amino acids of more than one of the domains CH1, hinge, CH2, and CH3,

wherein the remaining amino acids of the domain-modified human constant region have at least 80% the same amino acid sequence as that of at least one domain of the original human constant region,

wherein the antibody fragment is an IgG class antibody fragment with the proviso that it does not have an IgG3 heavy chain."

Independent claim 2 is also directed to an antibody fragment, but differs from claim 1 in that the domain-modified human constant region comprises "a deletion of the amino acids of the domains hinge, CH2, and CH3", the proviso with respect to IgG3 having been deleted. Independent claim 3 is identical to claim 1 of the second auxiliary request, except for the phrase "and wherein said human antibody is an IgG1 through IgG4 subclass antibody with the proviso that said human antibody is not an IgG3 subclass antibody" being replaced by "and wherein the antibody is an IgG class antibody with the proviso that it does not have an IgG3 heavy chain." Dependent claims 4 and 5 relate to different embodiments of the antibodies/antibody fragments of claims 1 to 3. Dependent claims 6 to 8 concern various embodiments of the antibody of claim 3, and independent claim 9 is directed to a method for producing the antibodies/antibody fragments of claims 1 to 3.

IX. Auxiliary request V (claims 1 to 9) differs from the previous request in that the negative proviso in independent claims 1 and 3 has been replaced by a positive formulation to the effect that the claimed antibody/antibody fragment is an IgG1, IgG2 or IgG4 subclass antibody/antibody fragment.

X. In auxiliary request VI, independent claim 2 includes a proviso by which antibody fragments having an IgG3 heavy chain are excluded from the scope of the claim, all other claims being identical to those of the previous request.

XI. Auxiliary request VII differs from the previous request in that the proviso has been replaced by a limiting feature analogous to that in claim 1 (cf. Section IX above).

XII. The claims of auxiliary request VIII have been limited to antibodies/antibody fragments of the IgG1 or IgG4 subclass (claims 1 to 8) and to a method for producing the same (claim 9).

XIII. Claims 1 to 4 of auxiliary request IX are identical to claims 2, 4, 5 and 9 of the previous request.

XIV. The respondent (opponent) submitted its comments on both the grounds of appeal and the new sets of claims filed by the appellant, and requested that oral proceedings be held in the event that the board did not intend to reject the appeal.

XV. The parties were summoned to oral proceedings to take place on 15 September 2005. In a communication pursuant to Article 11(1) of the Rules of Procedure of the Boards of Appeal sent with the summons, the board stated its provisional opinion on the issues decided by the opposition division and, in connection with the allowability of claim 1 of the second and third auxiliary requests under Article 123(2) EPC, drew the attention of the parties to decisions G 1/03 and G 2/03 (OJ EPO 2004, 413 and 448) of the Enlarged Board of Appeal, as well as to decision T 1050/99 of 25 January 2005. With regard to the auxiliary requests IV to IX filed on appeal, the board expressed its concerns as to the compliance of the new auxiliary requests with the requirements of Rule 57a and Articles 84, 123(2) and (3) EPC, and advised the appellant to submit new claim request(s) and to indicate the basis in the application as filed for each of the amendments introduced into these claims. Finally, the board commented on the issue of inventive step, referring in particular to decision T 939/92 (OJ EPO 1996, 309).

XVI. With letter dated 2 September 2005, the appellant withdrew its request for oral proceedings and requested instead that a decision be taken on the basis of the submissions in writing. No submissions were made in reply to the board's communication, nor were amended claim requests filed. The respondent also withdrew its request for oral proceedings, provided that the appeal would be rejected. On 12 September 2005 the parties were informed per fax letter that the oral proceedings were cancelled.

XVII. Following documents are referred to in the present decision:

D6: S. Cabilly et al., Proc. Natl. Acad. Sci. USA, June 1984, Vol. 81, pages 3273 to 3277;

D10: S.L. Morrison et al., Annals N.Y. Acad. Sci., December 1987, Vol. 507, pages 187 to 198.

XVIII. The submissions made by the appellant in writing, as far as they are relevant to this decision, were as follows:

The impugned decision stated that claim 1 of the second auxiliary request did not meet the requirements of Article 123(2) EPC because there was no specific disclosure of an IgG3 subclass human antibody. However, the application did disclose an IgG3 subclass antibody in Examples 1-3 of the specification, inter alia on page 16, lines 36-37; page 17, line 5; page 17, lines 17-19; page 18, line 5; and Figures 1 and 3. The proviso specifying that the claimed human antibody did not have an IgG3 heavy chain, was to disclaim cited reference D10, which described antibodies having deletions of domains wherein the antibody has an IgG3 heavy chain, for instance on page 193, line 22. Thus, the proviso conformed as a disclaimer to the requirements of Article 123(2) EPC. Consequently, the decision was incorrect in refusing to allow maintenance of the patent on the basis of the second auxiliary request.

The application clearly described half antibodies as claimed in claim 1 of auxiliary requests IV to IX. It was stated on page 16, lines 18-20 of the application as filed that the term "antibody" referred to both whole antibodies and fragments thereof, while page 16, lines 22-24 stated that antibody fragments included half antibodies formed from single light and heavy chains that have assembled to produce a specific binding site. Accordingly, the application provided an antibody fragment which comprised a half antibody formed from a single light chain and a single heavy chain assembled to produce a specific binding site.

XIX. The submissions made by the respondent in writing were essentially as follows:

No valid appeal was filed in respect of the main, first and third auxiliary requests, as the appellant did not provide any grounds on which the appeal was based. Therefore, these requests should be removed from consideration in the present proceedings.

There was no basis in the application as filed for excluding IgG3 antibodies from the claims. The application as filed mentioned IgG3 antibodies, but there was no statement in the application that it was preferred not to use IgG3 antibodies.

Document D10 was relevant for both novelty and inventive step issues. It was relevant also for questions of Article 123(2) EPC in connection with claim 1 of the second auxiliary request, since according to the established case law of the boards of appeal the use of a disclaimer in respect of a document relevant for obviousness was not possible.

Claim 1 of auxiliary request IV related to half antibodies. However, the passage of the application indicated by the appellant as support for this claim gave no details at all as to the structure of the half antibody. There was no disclosure in the application that half antibodies were only produced by making deletions in the constant region, as specified in claim 1. There was also no support for half antibodies in connection with the limitation to an IgG subclass. The combination claimed in claim 1 could not be derived directly and unambiguously from the application as filed. To come up with the wording of claim 1, the appellant had to take disclosures from disparate parts of the application and cobble them together. The same applied mutatis mutandis to claim 1 of the remaining auxiliary requests.

The amendments introduced in the claims raised deficiencies under Article 84. As regards conciseness, auxiliary requests IV to VIII contained three independent product claims. As regards clarity, when read in connection with the further features in claims 1 and 2, the phrase "the antibody fragment is an IgG class antibody" in these claims had no clear meaning.

The patent did not provide any guidance as to how to obtain half antibodies having certain combinations of deletions in the constant region specified in claim 1, for instance, a deletion of only CH2 and CH3. Such half antibodies could not be obtained, because the heavy chain containing a hinge region would dimerize to form a F(ab')2 molecule. A dimer having the features specified in claim 1 was already known from D10. Consequently, to the extent that the subject-matter of claim 1 was supported or enabled, it lacked novelty over D10. Furthermore, in view of this prior art document the subject-matter of all claims did not involve an inventive step.

XX. The appellant requests that the decision under appeal be set aside and the patent be maintained on the basis of the main request or any of the first auxiliary request filed on 30 July 1998, the second and third auxiliary requests filed on 18 August 2000 and auxiliary requests IV to IX filed with the statement of grounds of appeal.

XXI. The respondent requests that the appeal be dismissed.

Main request and first auxiliary request - Article 54 EPC

1. No reasons have been given by the appellant in its statement of grounds of appeal to substantiate its allegation that the findings of the opposition division with respect to the main request and the first auxiliary request were wrong. Since the board has been given no grounds, as would be required by Article 108 EPC, as to why the decision of the first instance on the present main request and first auxiliary request is wrong, these requests will not be considered by the board. It is not part of the function of the board of appeal to reconsider refused requests in the absence of any substantiation of their allowability under the EPC by the appellant.

Second and third auxiliary request - Article 123(2) EPC

2. Claim 1 of both the second and third auxiliary requests includes the feature "with the proviso that said human antibody is not an IgG3 subclass antibody", which was not present in claim 1 as granted. The opposition division found that this feature had no basis in the application as filed, the limitation to a human antibody of the IgG1 through IgG4 subclass, as disclosed on page 5, line 22 of the application as originally filed (corresponding to line 33 on page 3 of the application as published) not being considered to amount to a specific disclosure of an IgG3 subclass human antibody. Furthermore, the opposition division held that, even if the negative feature at issue were to be considered as a "disclaimer", no indication had been given by the proprietor as to which specific prior art disclosure might have served as a basis for it. Consequently, the amendment to claim 1 was found not to conform to Article 123(2) EPC (cf. point 4.3 of the impugned decision).

3. In the statement of grounds of appeal, the appellant contested these findings, pointing to further passages of the application as filed, which, in its view, provided a basis for the negative feature in amended claim 1. Thus, the first issue to be decided by the board in connection with Article 123(2) EPC is whether or not the application as filed, in particular the passages referred to in the impugned decision and/or cited by the appellant in its statement of grounds of appeal, disclose the negative feature in question.

4. The passage referred to in the decision of the opposition division (cf. point 4.3) is found in the application as filed under the heading "Description of the specific embodiments", and describes specific embodiments of the claimed antibodies. The whole sentence including this passage reads:

"The antibodies include IgM, IgG, IgA, IgD and IgE classes as well as the various subclasses of the individual classes (e.g., human IgG1 through IgG4)."

Further passages cited by the appellant in its statement of grounds of appeal read:

"IgG3 genes have been constructed and expressed." (page 16, lines 36-37 of the application as filed, corresponding to page 7, line 23 of the published application.)

"Exchanging the hinge region from IgG3 and IgG4 did not alter the ability of these molecules to fix complement and to bind the Fc receptor." (page 17, lines 5-7 of the application as filed, corresponding to page 7, lines 26-27 of the published application.)

"To determine if there is an upper limit on the size of an antibody molecule which could be produced, an IgG3 heavy chain in which CH1 and the hinge region were duplicated was constructed." (page 17, lines 16-19 of the application as filed, corresponding to page 7, lines 35-36 of the published application.)

"IgG3 heavy chain genes encoding proteins with deletions of

CH2;

hinge + CH2;

CH1 + hinge; and

CH1 + hinge + CH2

were constructed and transfected into myeloma cells" (page 18, lines 5-10 of the application as filed, corresponding to page 7, lines 50-55 of the published application.)

The appellant cited also Figures 1 and 3 as disclosing an IgG3 subclass antibody. In Figure 1, four different cloning cassettes used to exchange constant regions are shown, each cassette corresponding to one of the four IgG subclasses, ie IgG1, IgG2, IgG3 and IgG4. Figure 3 illustrates a cloning cassette used to delete or duplicate constant region domains, in particular of an antibody of the IgG3 subclass.

5. When judging whether or not amendments introduced in the claims conform to Article 123(2) EPC, the Boards of Appeal of the EPO take a strict approach (cf. "Case Law of the Boards of Appeal of the EPO", 4th edition 2001, chapter III.A). An amendment is only considered to be allowable if the skilled person can derive the subject-matter of the amended claim from the application in a clear and unambiguous manner. This board does not see any reason to deviate from this jurisprudence when judging whether or not a negative feature introduced in the claims adds subject-matter contrary to Article 123(2) EPC.

6. In the present case, the board notes that, although IgG3 subclass antibodies are in fact mentioned in all the passages of the application quoted above, no explicit formal basis for the introduced amendment as such, ie for a negative feature excluding specifically IgG3 subclass antibodies can be found in the cited passages or elsewhere in the application as filed. Moreover, the board is not able to find an implicit support for the claimed subject-matter in the cited passages, as the embodiments being excluded by the negative feature in question (ie IgG3 subclass antibodies) are presented as being part of the invention disclosed in the application, rather than as an area which should be excluded or avoided, as it is the case in claim 1 (cf. decision T 1050/99 of 25 January 2005, in particular point 7(c) of the reasons). For these reasons, the passages of the application as filed cited by the appellant cannot be accepted as an explicit or implicit basis for the negative feature introduced in claim 1.

7. On appeal, the appellant has alleged that the negative feature in claim 1 is intended to disclaim the subject-matter disclosed in document D10, and, as a disclaimer, conforms to the requirements of Article 123(2) EPC. In view of the appellant's submission, a further question to be decided by the board in this respect is whether in the present case the introduction of the undisclosed disclaimer in claim 1 conforms to Article 123(2) EPC.

8. In decisions G 1/03 and G 2/03 (OJ EPO 2004, 413 and 448), the Enlarged Board of Appeal established the criteria for assessing whether an amendment to a claim by introduction of an undisclosed disclaimer offends against Article 123(2) EPC. According to these decisions, the introduction of an undisclosed disclaimer may be allowable under certain circumstances, inter alia, in order to restore novelty by delimiting a claim against state of the art under Article 54(3) and (4) EPC or against an accidental anticipation under Article 54(2) EPC (cf. G 1/03, supra, Headnote II.1).

9. None of these exceptional circumstances apply in the present case. Document D10, which belongs to the prior art citable under Article 54(2) EPC and discloses human domain-modified constant region antibodies, has been considered to be possibly the "closest prior art", ie the starting point for the assessment of inventive step, by both the appellant and the respondent. Therefore, this document can hardly be considered to be an "accidental anticipation" as defined in the decisions G 1/03 and G 2/04 (supra), ie a prior art document which is so unrelated to and remote from the claimed invention that the person skilled in the art would never have taken it into consideration when making the invention. Moreover, if one takes this document as starting point for the assessment of inventive step, the negative feature included in claim 1 becomes relevant in this respect as, at least for certain embodiments encompassed by claim 1, it constitutes the only difference over the disclosure of the prior art.

10. In the light of these considerations, the board concludes that the amendment to claim 1 of the second and third auxiliary requests by introduction of the disclaimer in question is not allowable, as it adds subject-matter contrary to Article 123(2) EPC.

Auxiliary requests IV to IX - Article 123(2) EPC

11. With the statement of grounds of appeal, the appellant filed six new auxiliary requests, all of which include at least one independent claim directed to an antibody fragment which comprises a half antibody (cf. Sections VIII to XIII above). The respondent has protested against the introduction of the new requests, raising numerous objections under Articles 123(2), 84, 83, 54 and 56 EPC.

12. In its communication pursuant to Article 11(1) of the Rules of Procedure, the board indicated that, in spite of the references to the original application given by the appellant in the statement of grounds of appeal, the origin and rationale of the amendments introduced in the new auxiliary requests in comparison to the claims as granted and to the claims submitted before the opposition division, was not clear. The board also indicated that it was an undue burden for the reader to establish: 1) in response to which objection any given feature had been introduced in the claim, 2) whether a given feature found its origin in the application as filed in relation to the whole of the other features specified in the claim, and 3) whether the scope of protection had remained the same.

13. The board also indicated that the auxiliary requests IV to IX might raise serious issues under Rule 57a and Articles 84, 123(2) and 123(3) EPC. Specifically, in connection with Article 123(2) EPC the board pointed to claims 1 and 2 of auxiliary requests IV to VIII, and claim 1 of auxiliary request IX, which read: "An antibody fragment which comprises a half antibody...", and took the view that, whereas it was stated on page 16, lines 22-24 of the application as filed that antibody fragments within the meaning of the application may be half antibodies formed from single light and heavy chains that have assembled to produce a specific binding site, none of the passages cited by the appellant in its statement of grounds of appeal appeared to provide a fair basis for antibody fragments including anything else than a half antibody.

14. As this particular deficiency under Article 123(2) EPC, which has been mentioned in the board's communication, affects claim 1 of each of the auxiliary requests IV to IX, none of these claim requests can serve as a basis for the maintenance of the patent. Consequently, in the absence of an allowable claim request the board cannot set aside the impugned decision as requested by the appellant.

Article 113(1) EPC

15. The reasons given in the present decision were apparent from the communication sent by the board in preparation for the oral proceedings. The appellant withdrew its request for oral proceedings, and chose not to file a reply to the board's communication or amended claim requests. The respondent's request for oral proceedings is conditional, and the matter is decided in its favour. Thus, the provisions of Article 113(1) EPC are complied with.

Order

ORDER

For these reasons it is decided that:

The appeal is dismissed.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility